Supplementary Figure 1 from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Supplemental Figure 1: P-AscH- treatment in combination with RT and TMZ decreases the systemic the systemic oxidaitive stress marker 4-hydroxy-2-nonenal modified proteins. S1A-SAB.